Determination of Immune Surveillance in Cerebrospinal Fluid (CSF) in Patients with Crohnʼs Disease: Initial Results of the TOSCA Study
William J. Sandborn(University of San Diego), Walter Reinisch(Medical University of Vienna), Richard M. Ransohoff(Cleveland Clinic Lerner College of Medicine), Olaf Stüve(Southwestern Medical Center), Fabio Cataldi(Pfizer (United States)), Gail M. Comer(Pfizer (United States)), Geert D’Haens(Amsterdam University Medical Centers), Mina Hassan‐Zahraee(Pfizer (United States)), Bo Jin(Radboud University Nijmegen), Sunday Rivers(Pfizer (United States)), Jenny Zhang(Pfizer (United States)), Kenneth J. Gorelick, A. Van Gossum(Université Libre de Bruxelles), John Cheng(Pfizer (United States))
Cited by 0
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Crohn's disease
|The Lancet|2012|2.1k